Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT02935790 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: ACY-241
DRUG: nivolumab
DRUG: ipilimumab

Sponsor

Celgene

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]